Drug
Natalizumab
Natalizumab: highest development phase Approved, developed by Biogen. 3 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| TYSABRI | Approved | |
| Natalizumab NCT00030966 | Phase 3 | Multiple Sclerosis, Relapsing-Remitting |
| natalizumab NCT01416155 | Phase 2 | Relapsing-Remitting Multiple Sclerosis |
Latest
No recent events.
Follow Natalizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.